BACKGROUND: Pyoderma gangrenosum is a rare, destructive, ulcerative neutrophilic dermatosis of unknown origin that has been investigated insufficiently in clinical studies. According to current textbooks, it is often associated with chronic inflammatory bowel diseases or other autoimmune disorders. PATIENTS AND METHODS: We retrospectively analyzed data from 49 patients with pyoderma gangrenosum. RESULTS: Our results showed that although only 6.1 % of patients had chronic inflammatory bowel disease, 22.4 % patients had a malignancy, 18.4 % had chronic renal insufficiency, and 42.8 % had anemia. A potentially relevant aspect that has received little attention is an association with endocrine diseases in 38.8 % of patients. 28.6 % of patients had diabetes. Given that 32.6 % of patients were obese, a potential association with metabolic syndrome may be considered as a possible new risk factor for pyoderma gangrenosum. CONCLUSIONS: The clinical data from the present study are insufficient for drawing any firm conclusions. We did, however, observe an association between pyoderma gangrenosum and certain as yet unreported co-factors, in particular metabolic syndrome. This should be considered in further studies.
BACKGROUND:Pyoderma gangrenosum is a rare, destructive, ulcerative neutrophilic dermatosis of unknown origin that has been investigated insufficiently in clinical studies. According to current textbooks, it is often associated with chronic inflammatory bowel diseases or other autoimmune disorders. PATIENTS AND METHODS: We retrospectively analyzed data from 49 patients with pyoderma gangrenosum. RESULTS: Our results showed that although only 6.1 % of patients had chronic inflammatory bowel disease, 22.4 % patients had a malignancy, 18.4 % had chronic renal insufficiency, and 42.8 % had anemia. A potentially relevant aspect that has received little attention is an association with endocrine diseases in 38.8 % of patients. 28.6 % of patients had diabetes. Given that 32.6 % of patients were obese, a potential association with metabolic syndrome may be considered as a possible new risk factor for pyoderma gangrenosum. CONCLUSIONS: The clinical data from the present study are insufficient for drawing any firm conclusions. We did, however, observe an association between pyoderma gangrenosum and certain as yet unreported co-factors, in particular metabolic syndrome. This should be considered in further studies.
Authors: Finja Jockenhöfer; Harald Gollnick; Katharina Herberger; Georg Isbary; Regina Renner; Markus Stücker; Eva Valesky; Uwe Wollina; Michael Weichenthal; Sigrid Karrer; Bernhard Kuepper; Alexander Roesch; Joachim Dissemond Journal: Int Wound J Date: 2014-12-05 Impact factor: 3.315
Authors: Finja Jockenhöfer; Joachim Klode; Knut Kröger; Alexander Roesch; Philipp Al Ghazal; Joachim Dissemond Journal: Int Wound J Date: 2015-08-06 Impact factor: 3.315
Authors: Hovik J Ashchyan; Daniel C Butler; Caroline A Nelson; Megan H Noe; William G Tsiaras; Stephen J Lockwood; William D James; Robert G Micheletti; Misha Rosenbach; Arash Mostaghimi Journal: JAMA Dermatol Date: 2018-04-01 Impact factor: 10.282